ADVOCACY

Position Statements & Letters

The AMP advocacy program endeavors to inform and influence public policy affecting molecular pathology. AMP represents its membership to the federal agencies and members of Congress regarding professional and reimbursement issues - reaching out to fellow professional associations, industry and other association partners to accomplish common goals. Position statements, comments, and letters are usually generated by our Professional Relations and Economic Affairs Committees, though our Clinical Practice and Training & Education Committees do advocate in their areas.

We invite you to explore AMP's Position Statements and Communications. For more information, please contact Mary Williams.

2019 Position Statements and Letters

 
Date Title Keywords Committee
August 11 Joint Comments on First Coast Proposed Local Coverage Determination: Gastrointestinal Pathogen (GIP) Panels Utilizing Multiplex Nucleic Acid Amplification Techniques (NAATs) First Coast, dLCD, NAATs, GIP Economic Affairs
August 11 Joint Comments on Novitas Proposed Local Coverage Determination: Gastrointestinal Pathogen (GIP) Panels Utilizing Multiplex Nucleic Acid Amplification Techniques (NAATs) (DL38229) Novitas, dLCD, NAATs, GIP Economic Affairs
July 25 Updated List of Signers: Coalition Letter Opposing Draft Legislation of Section 101 of the Patent Act Gene Patents, ACLU, Patent Reform Professional Relations
June 20 Joint Comments on MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies (DL38047) LCD, CAP, NGS, MolDX Economic Affairs
June 20 Joint Comments on MolDX: Next-Generation Sequencing for Solid Tumors (DL38045) LCD, CAP, NGS, MolDX Economic Affairs
June 10 AMP Position Statement:
Consumer Genomic Testing – June 2019		 Genomic testing Professional Relations
June 3 Coalition Letter Opposing Draft Legislation of Section 101 of the Patent Act Gene Patents, ACLU, Patent Reform Professional Relations
May 29 Comments on the Reconsideration of the National Coverage Determination on Next Generation Sequencing (NGS) for Medicare Beneficiaries with Advanced Cancer CMS, NGS NCD, MAC, germline testing Economic Affairs
May 20 Group Stakeholder Letter Requesting Comment Period Extension on the Reconsideration of the National Coverage Determination on Next Generation Sequencing (NGS) for Medicare Beneficiaries with Advanced Cancer CMS, NGS NCD, MAC Economic Affairs
May 4 Joint Comments on the FDA Guidance on Informed Consent for In Vitro Diagnostic Device Studies Using Leftover Human Specimens that are Not Individually Identifiable FDA, ASIP, Common Rule Professional Relations
March 18 AMP Comments on the "BRCA-Related Cancer: Risk Assessment, Genetic Counseling, and Genetic Testing" Draft Recommendation Statement Published by the US Preventative Services Task Force (USPSTF) USPSTF, BRCA1, BRCA2, NCCN Professional Relations
March 17 Stakeholder Sign on Letter to CMS Regarding the Revisions to the National Correct Coding Initiative (NCCI) Policy Manual CMS, NCCI, PTP edits Economic Affairs
March 4 AMP Comments on the Revisions to the National Correct Coding Initiative (NCCI) Policy Manual CMS, NCCI, PTP edits Economic Affairs
March 1 AMP Comments on the Clinical Laboratory Improvement Amendments of 1988 (CLIA) Fees CMS, CLIA Professional Relations
February 13 AMP Comments on the Draft Discussion of the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2018 VALID, LDPs, LDTs, FDA, CMS, CLIA, IVDs, IVCTs Professional Relations
February 5 Comments on the FDA Draft Guidance titled "Developing and Labeling In vitro Companion Diagnostic Devices for a Specific Group or Class of Oncology Therapeautic Products Guidance for Industry" FDA, Companion Diagnostics, Oncology Professional Relations
February 1 Stakeholder Sign on Letter to CMS Regarding National Coverage Determination for Next Generation Sequencing for Medicare Patient with Advanced Cancer NGS, CMS, FDA, NCD, MAC Economic Affairs, Professional Relations

Corporate Partners